I think this slide very well may be the most important in the new deck. Eftilagimod alpha very well may turn NSCLC and HNSCC into PD-L1 all comers, but knowing who’s like to clinically benefit once on drug could be the key. I bet Merck scientists or the FDA had something to do with this, as in creating boxes to check in the trial. Having a biomarker plan explaining response is “the way”. https://www.immutep.com/files/content/investor/presentation/2024/Immutep%20Corporate%20Presentation%20March%202024.pdf
Media, page-682
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $1.220M | 3.642M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 57289 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 52306 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |